The Secret Life of Viral Entry Glycoproteins: Moonlighting in Immune Evasion

1. SanchezA, LukwiyaM, BauschD, MahantyS, SanchezAJ, et al. (2004) Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol 78: 10370–10377.

2. QiuX, AudetJ, WongG, PilletS, BelloA, et al. (2012) Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 4: 138ra181.

3. WhiteJM, DelosSE, BrecherM, SchornbergK (2008) Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit Rev Biochem Mol Biol 43: 189–219.

4. JeffersSA, SandersDA, SanchezA (2002) Covalent modifications of the Ebola virus glycoprotein. J Virol 76: 12463–12472.

5. RitchieG, HarveyDJ, StroeherU, FeldmannF, FeldmannH, et al. (2010) Identification of N-glycans from Ebola virus glycoproteins by matrix-assisted laser desorption/ionisation time-of-flight and negative ion electrospray tandem mass spectrometry. Rapid Commun Mass Spectrom 24: 571–585.

6. WilsonJA, HeveyM, BakkenR, GuestS, BrayM, et al. (2000) Epitopes involved in antibody-mediated protection from Ebola virus. Science 287: 1664–1666.

7. PantophletR, BurtonDR (2006) GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24: 739–769.

8. OuW, DelisleJ, JacquesJ, ShihJ, PriceG, et al. (2012) Induction of Ebola virus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain. Virol J 9: 32.

9. DiasJM, KuehneAI, AbelsonDM, BaleS, WongAC, et al. (2011) A shared structural solution for neutralizing Ebola viruses. Nat Struct Mol Biol 18: 1424–1427.

10. SimmonsG, Wool-LewisRJ, BaribaudF, NetterRC, BatesP (2002) Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J Virol 76: 2518–2528.

11. ReynardO, BorowiakM, VolchkovaVA, DelpeutS, MateoM, et al. (2009) Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface proteins. J Virol 83: 9596–9601.

12. LeeJE, FuscoML, HessellAJ, OswaldWB, BurtonDR, et al. (2008) Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454: 177–182.

13. FrancicaJR, Varela-RohenaA, MedvecA, PlesaG, RileyJL, et al. (2010) Steric shielding of surface epitopes and impaired immune recognition induced by the Ebola virus glycoprotein. PLoS Pathog 6: e1001098 doi:10.1371/journal.ppat.1001098.

14. SanchezA, YangZY, XuL, NabelGJ, CrewsT, et al. (1998) Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J Virol 72: 6442–6447.

15. DolnikO, VolchkovaV, GartenW, CarbonnelleC, BeckerS, et al. (2004) Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J 23: 2175–2184.

16. ItoH, WatanabeS, TakadaA, KawaokaY (2001) Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J Virol 75: 1576–1580.

17. DruarC, SainiSS, CossittMA, YuF, QiuX, et al. (2005) Analysis of the expressed heavy chain variable-region genes of Macaca fascicularis and isolation of monoclonal antibodies specific for the Ebola virus' soluble glycoprotein. Immunogenetics 57: 730–738.

18. MaruyamaT, ParrenPW, SanchezA, RensinkI, RodriguezLL, et al. (1999) Recombinant human monoclonal antibodies to Ebola virus. J Infect Dis 179 Suppl 1: S235–239.

19. CiancioloGJ, CopelandTD, OroszlanS, SnydermanR (1985) Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins. Science 230: 453–455.

20. MorozovVA, MorozovAV, SemaanM, DennerJ (2012) Single mutations in the transmembrane envelope protein abrogate the immunosuppressive property of HIV-1. Retrovirology 9: 67.

21. YaddanapudiK, PalaciosG, TownerJS, ChenI, SariolCA, et al. (2006) Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses. FASEB J 20: 2519–2530.

22. MangeneyM, HeidmannT (1998) Tumor cells expressing a retroviral envelope escape immune rejection in vivo. Proc Natl Acad Sci U S A 95: 14920–14925.

23. MangeneyM, RenardM, Schlecht-LoufG, BouallagaI, HeidmannO, et al. (2007) Placental syncytins: genetic disjunction between the fusogenic and immunosuppressive activity of retroviral envelope proteins. Proc Natl Acad Sci U S A 104: 20534–20539.

24. DupressoirA, LavialleC, HeidmannT (2012) From ancestral infectious retroviruses to bona fide cellular genes: role of the captured syncytins in placentation. Placenta 33: 663–671.

25. MoldenhauerG, HenneC, KarhausenJ, MollerP (1999) Surface-expressed invariant chain (CD74) is required for internalization of human leucocyte antigen-DR molecules to early endosomal compartments. Immunology 96: 473–484.

26. CresswellP (1994) Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol 12: 259–293.

27. BashaG, OmilusikK, Chavez-SteenbockA, ReinickeAT, LackN, et al. (2012) A CD74-dependent MHC class I endolysosomal cross-presentation pathway. Nat Immunol 13: 237–245.

28. ZhouC, LuL, TanS, JiangS, ChenYH (2011) HIV-1 glycoprotein 41 ectodomain induces activation of the CD74 protein-mediated extracellular signal-regulated kinase/mitogen-activated protein kinase pathway to enhance viral infection. J Biol Chem 286: 44869–44877.

29. ChangTL, GordonCJ, Roscic-MrkicB, PowerC, ProudfootAE, et al. (2002) Interaction of the CC-chemokine RANTES with glycosaminoglycans activates a p44/p42 mitogen-activated protein kinase-dependent signaling pathway and enhances human immunodeficiency virus type 1 infectivity. J Virol 76: 2245–2254.

30. DunnSJ, KhanIH, ChanUA, ScearceRL, MelaraCL, et al. (2004) Identification of cell surface targets for HIV-1 therapeutics using genetic screens. Virology 321: 260–273.

31. NeilSJ, ZangT, BieniaszPD (2008) Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451: 425–430.

32. KaletskyRL, FrancicaJR, Agrawal-GamseC, BatesP (2009) Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci U S A 106: 2886–2891.

33. LauD, KwanW, GuatelliJ (2011) Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens. J Virol 85: 9834–9846.

34. LopezLA, YangSJ, HauserH, ExlineCM, HaworthKG, et al. (2010) Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J Virol 84: 7243–7255.

35. LopezLA, YangSJ, ExlineCM, RengarajanS, HaworthKG, et al. (2012) Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts. J Virol 86: 5467–5480.

36. SkaskoM, WangY, TianY, TokarevA, MunguiaJ, et al. (2012) HIV-1 Vpu protein antagonizes innate restriction factor BST-2 via lipid-embedded helix-helix interactions. J Biol Chem 287: 58–67.

37. BrancoLM, GroveJN, MosesLM, GobaA, FullahM, et al. (2010) Shedding of soluble glycoprotein 1 detected during acute Lassa virus infection in human subjects. Virol J 7: 306.

38. BrancoLM, GarryRF (2009) Characterization of the Lassa virus GP1 ectodomain shedding: implications for improved diagnostic platforms. Virol J 6: 147.

39. ChiangSF, LinTY, ChowKC, ChiouSH (2010) SARS spike protein induces phenotypic conversion of human B cells to macrophage-like cells. Mol Immunol 47: 2575–2586.

40. KongL, GiangE, RobbinsJB, StanfieldRL, BurtonDR, et al. (2012) Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proc Natl Acad Sci U S A 109: 9499–9504.

41. HelleF, VieyresG, ElkriefL, PopescuCI, WychowskiC, et al. (2010) Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J Virol 84: 11905–11915.

42. CrottaS, StillaA, WackA, D'AndreaA, NutiS, et al. (2002) Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 195: 35–41.

43. MachielsB, LétéC, GuillaumeA, MastJ, StevensonPG, et al. (2011) Antibody evasion by a gammaherpesvirus O-glycan shield. PLoS Pathog 7: e1002387 doi:10.1371/journal.ppat.1002387.

44. RessingME, van LeeuwenD, VerreckFA, KeatingS, GomezR, et al. (2005) Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion. J Virol 79: 841–852.

45. WeiCJ, BoyingtonJC, DaiK, HouserKV, PearceMB, et al. (2010) Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci Transl Med 2: 24ra21.

46. DasSR, PuigbòP, HensleySE, HurtDE, BenninkJR, et al. (2010) Glycosylation focuses sequence variation in the influenza A virus H1 hemagglutinin globular domain. PLoS Pathog 6: e1001211 doi:10.1371/journal.ppat.1001211.

47. BukreyevA, YangL, FrickeJ, ChengL, WardJM, et al. (2008) The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J Virol 82: 12191–12204.

48. AguilarHC, MatreyekKA, FiloneCM, HashimiST, LevroneyEL, et al. (2006) N-glycans on Nipah virus fusion protein protect against neutralization but reduce membrane fusion and viral entry. J Virol 80: 4878–4889.

49. MooreJP, SodroskiJ (1996) Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol 70: 1863–1872.

50. Schlecht-LoufG, RenardM, MangeneyM, LetzelterC, RichaudA, et al. (2010) Retroviral infection in vivo requires an immune escape virulence factor encrypted in the envelope protein of oncoretroviruses. Proc Natl Acad Sci U S A 107: 3782–3787.

51. McLellanJS, PanceraM, CarricoC, GormanJ, JulienJP, et al. (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480: 336–343.

52. CohenT, CohenSJ, AntonovskyN, CohenIR, ShaiY (2010) HIV-1 gp41 and TCRα trans-membrane domains share a motif exploited by the HIV virus to modulate T-cell proliferation. PLoS Pathog 6: e1001085 doi:10.1371/journal.ppat.1001085.

53. AshkenaziA, FaingoldO, KaushanskyN, Ben-NunA, ShaiY (2013) A highly conserved sequence associated with the HIV gp41 loop region is an immunomodulator of antigen-specific T cells in mice. Blood 121: 2244–2252.